Phase I study of the combination of alpha-2 interferon and cisplatinum

C. Walsh, J. L. Speyer, J. Wernz, H. Hochster, H. Grossberg, A. Chachoua, P. Molinaro, M. Meyers, R. H. Blum

Research output: Contribution to journalArticlepeer-review

19 Scopus citations

Abstract

Based on preclinical evidence of synergy, we performed a Phase I study of the combination of alpha-2 interferon and cisplatinum in patients with advanced malignancy. A fixed dose of 5 x 106 U/m2 alpha interferon was given 3 times weekly. Cisplatinum was given once weekly at dose levels of 5, 10, 20, 25, and 30 mg/m2. Dose-limiting toxicity consisted of flu-like symptoms and malaise leading to decreased performance status. Response was seen in a patient with metastatic melanoma. Recommended doses for Phase II study are 5 x 106 U/m2 of alpha-2 interferon 3 times weekly and 25 mg/m2 of cisplatinum once weekly.

Original languageEnglish (US)
Pages (from-to)11-15
Number of pages5
JournalJournal of Biological Response Modifiers
Volume8
Issue number1
StatePublished - Jan 1 1989
Externally publishedYes

All Science Journal Classification (ASJC) codes

  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'Phase I study of the combination of alpha-2 interferon and cisplatinum'. Together they form a unique fingerprint.

Cite this